On July 20, Joinn Laboratories (06127.HK) rose 6.9% in regular trading, trading at HK$25.06 per share, with turnover of HK$203 million.

On the news front, the company previously disclosed its H1 earnings guidance, projecting attributable net profit of RMB 600 million to RMB 900 million, representing year-over-year growth of 884.9% to 1,377.4%. The surge was primarily driven by biological asset fair value changes contributing approximately RMB 703 million to RMB 777 million in net profit, as experimental monkey market prices broke through RMB 200,000 per unit combined with natural growth appreciation.

Meanwhile, the broader CXO sector continued its rebound trend, with peers including WuXi Biologics, Pharmaron, and WuXi XDC posting broad gains on the day. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 3.53%, WUXI BIO gained 4.65%, INSILICO advanced 5.14%, PHARMARON climbed 5.95%, and WUXI XDC added 5.44%, reflecting improving sector sentiment that provided additional support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)